MarketVIEW STD & Sexual Health Vaccines  ·  April 2025 edition

Herpes Simplex Virus (HSV-1/2)
Therapeutic Vaccines Forecast

HSV-2 alone affects over half a billion people worldwide, and a therapeutic vaccine able to suppress disease and reduce transmission has been pursued for decades. GSK's most advanced recent candidate missed its endpoint in 2024, leaving Moderna and BioNTech's mRNA programmes as the field's best remaining hope. This is the independent commercial assessment of what comes next, drawing on VacZine Analytics' long-standing, independent authority in STD vaccine markets.

GSK Candidate Missed Endpoint (2024) 519.5M Living With HSV-2 20 Nations Modelled mRNA Candidates in Phase 1/2
Product catalogue
VAMV038
April 2025 edition

Format
PDF (~180 slides) + Excel
Coverage
20 nations, public & private
Vaccines assessed
GSK, mRNA-1608, BNT163
Markets
North America, EU, Australia, Japan
Approach
Scenario-based
Base edition
April 2025
Availability
Syndicated / bespoke
519.5M
People aged 15-49 living
with HSV-2 (WHO, 2020)
3.7bn
People infected with
HSV-1 worldwide
60-85%
Mortality rate for untreated
neonatal herpes
2024
Year GSK's leading candidate
missed its Phase 2 endpoint
Disease background

Why HSV has remained a therapeutic vaccine priority

Herpes simplex virus is one of the most widespread infections in humanity, and its recurring, often deeply distressing symptomatic disease has made a therapeutic vaccine a long-standing goal. Understanding the scale of that burden, and why the field's most recent leading candidate has just fallen short, is central to understanding what a workable vaccine could still be worth.

Peer-reviewed & 2026 pipeline data

Pathogen overview - Herpes simplex virus (HSV-1/HSV-2)

Herpes simplex virus types 1 and 2 are ubiquitous members of the human herpesvirus family, transmitted by oral or genital contact and establishing lifelong latent infection in sensory ganglia following primary exposure. Both types cause oral, ocular and/or genital infection, with genital ulcer disease (GUD) among the most consequential clinical manifestations. Most infected individuals have minimal or no recognised signs of infection, but a substantial minority experience frequent symptomatic reactivation, with considerable impact on sexual and reproductive health and psychological wellbeing.

WHO's most recent (2020) global modelling estimates that 519.5 million people aged 15 to 49 were living with HSV-2 worldwide, a 13.3% prevalence in that age group, with a further 25.6 million new infections that year, an upward revision from the 491 million (13.2%) estimated for 2016. HSV-1 is even more widespread, estimated to infect around 3.7 billion people worldwide, the majority of the global population under 50. Prevalence of both viruses is markedly higher in women and in lower-income regions, and HSV-2 is an important, and under-appreciated, contributor to global HIV incidence, particularly in low-income countries, where genital ulceration facilitates HIV acquisition and transmission.

Though rare, neonatal herpes carries a mortality rate of approximately 60 to 85% if untreated, among the most severe outcomes in all of neonatal infectious disease. Current management relies on antiviral therapy, aciclovir and valaciclovir, which suppress viral replication, reduce symptomatic recurrence and lower, but do not eliminate, the risk of transmission to sexual partners. None is curative, and none prevents infection in the first place.

A therapeutic vaccine able to suppress symptomatic disease and reduce transmission has long been viewed as a major unmet need, offering a more convenient administration profile and potentially long-lived protection over daily antiviral therapy. That hope met a setback in September 2024, when GSK terminated its therapeutic candidate GSK3943104A after it failed to meet its primary efficacy endpoint, preventing symptomatic HSV-2 disease, in a randomised study enrolling more than 3,000 participants, itself a successor to an earlier terminated self-amplifying mRNA candidate, GSK4108771A. Attention has since shifted to mRNA-based approaches from Moderna (mRNA-1608, therapeutic) and BioNTech (BNT163, primarily prophylactic but also under evaluation in people with recurrent disease), both still in Phase 1/2 testing, alongside smaller programmes from Eurocrine, Rational Vaccines and Simplexia.

2026 519.5M living with HSV-2  |  3.7bn with HSV-1  |  up to 85% neonatal herpes mortality if untreated  |  leading GSK candidate missed Phase 2
Product & competitor landscape

A field of repeated setbacks - and mRNA's next attempt

Therapeutic HSV vaccine development has a long history of disappointment. GSK's most recent candidate missed its endpoint in 2024, the latest in a string of setbacks stretching back decades. Moderna and BioNTech's mRNA candidates are now the field's best remaining hope, though neither has yet reached a pivotal trial.

  • GSKTerminated 2024
    GSK3943104A
    A therapeutic HSV-2 vaccine candidate, and GSK's second attempt in the field after previously terminating a self-amplifying mRNA candidate, GSK4108771A. A randomised study enrolling more than 3,000 participants failed to meet its primary efficacy endpoint of preventing symptomatic HSV-2 disease; GSK terminated the programme in September 2024.
  • ModernaPhase 1/2
    mRNA-1608 Therapeutic
    A therapeutic mRNA vaccine for genital herpes. The Phase 1/2 study (303 participants; NCT06033261) completed and posted full results in May 2026: recurrence over 12 months was lower with the highest mRNA-1608 dose than with the meningococcal-vaccine control (1.8 vs 2.8 episodes), alongside dose-dependent rises in gB/gC/gD antibody titres and no new safety signals, but the programme is still not expected to advance directly into Phase 3, one of several deprioritised in Moderna's recent pipeline review.
  • BioNTechPhase 1/2
    BNT163 Prophylactic + therapeutic arm
    A trivalent, lipid-nanoparticle-encapsulated mRNA vaccine encoding HSV-2 glycoproteins gC2, gD2 and gE2. Developed primarily as a prophylactic candidate, with an exploratory three-part trial that also evaluates safety and immunogenicity in people with recurrent genital herpes. Still in early clinical testing as of 2026.
  • Second-wave & smaller programmesVarious
    Eurocrine, Rational Vaccines and Simplexia
    Smaller therapeutic and prophylactic programmes from Eurocrine, Rational Vaccines and Simplexia continue in earlier development, representing a broader field still searching for a validated efficacy signal following GSK's 2024 setback.
Market reset
2024

GSK's 2024 Phase 2 miss is the latest in a decades-long string of HSV therapeutic vaccine disappointments, and it leaves mRNA-based candidates from Moderna and BioNTech as the field's best remaining hope, neither yet in a pivotal trial. The underlying opportunity has not gone away: HSV-2 alone affects over half a billion people aged 15 to 49, with a considerable and recurring impact on quality of life. The VacZine Analytics model quantifies the commercial opportunity under multiple pipeline-recovery scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW HSV therapeutic analysis spans disease burden, target-population rationale, the post-2024 competitor landscape and scenario-based revenue forecasting across 20 nations, public and private markets.

Patient forecast across 20 nations

Bottom-up modelling across 20 nations, public and private, including North America, Europe, Australia and Japan.

Competitor & pipeline review

GSK's 2024 Phase 2 miss, Moderna's mRNA-1608 and BioNTech's BNT163 exploratory data, and smaller programmes from Eurocrine, Rational Vaccines and Simplexia.

mRNA vs conventional modality

Examination of the merits of mRNA approaches relative to historical subunit, self-amplifying and live-attenuated strategies.

Scenario-based revenue forecasts

Base, upside and conservative scenarios across public and private markets and key target groups, with explicit assumptions.

Disease burden & epidemiology

Updated global HSV-1/HSV-2 prevalence, genital ulcer disease incidence, and the interaction with HIV acquisition and transmission.

Expert perspective & R&D strategy

Insight informed by the CDC/NIAID Joint Workshop on Herpes and discussion of next-generation vaccinology concepts.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Target populationGeographyMarket typeVaccine profileRevenue scenario
Recurrent genital herpes (HSV-2+)US + EU5Private + publicTherapeutic mRNAModelled
Prophylactic target cohort20-nationPublic programmeProphylactic mRNAModelled
Serodiscordant couplesGlobalPrivateSuppression / transmissionModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseGlobalAllAll profiles$███m
Full model in the licensed workbook
20 nations · public/private · target group · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the HSV therapeutic vaccine opportunity.

  • Executive presentation (~180 slides, PDF) - disease background, epidemiology, GSK's 2024 setback, competitor pipeline, expert workshop perspectives and full commercial assessment with supporting narrative and references
  • Interactive MS-Excel forecast model - scenario-based volume and revenue outputs across 20 nations, public and private markets
  • Scenario-based commercial forecasts - base, upside and conservative cases reflecting the post-2024 pipeline reset
  • Competitor intelligence - GSK, Moderna mRNA-1608, BioNTech BNT163, and smaller programmes (Eurocrine, Rational Vaccines, Simplexia)
  • Updated epidemiology module - WHO HSV-1/HSV-2 prevalence and genital ulcer disease modelling, neonatal herpes burden, and the HIV interaction
  • Expert perspective - insights from the CDC/NIAID Joint Workshop on Herpes and next-generation R&D strategy discussion
Target audience

Built for organisations weighing the HSV opportunity

Most valuable to teams evaluating the HSV therapeutic vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of GSK's 2024 setback and what it means for the mRNA candidates left standing.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for HSV candidates at any stage.

Corporate strategy & BD

Validate the market size and structure after GSK's 2024 setback, and understand what it means for mRNA competitors.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on HSV and adjacent STD vaccine assets.

Public health & STD programmes

Demand modelling for sexual health and STD-focused immunisation and prevention programmes.

Researchers & academia

Comprehensive epidemiology and the vaccine landscape for grant and translational planning, including the CDC/NIAID workshop findings.

Market access & policy

Pricing benchmarks and access-pathway assumptions across public and private sexual health channels.

About this analysis · VAMV038

VacZine Analytics has tracked STD vaccine markets since our earliest editions, positioning us to reassess HSV therapeutic vaccines the moment the pipeline changed. This analysis combines a rigorous epidemiological and clinical review with an independently constructed commercial model spanning 20 nations that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis.

This April 2025 edition incorporates GSK's September 2024 Phase 2 termination and the latest interim data from Moderna's mRNA-1608 and BioNTech's BNT163. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV038 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc HSV analysis, a briefing call is included on request.